MRNA·HealthcareSELL

Moderna, Inc.

Gianfranco Cacciola·June 8, 2026

Price Target

$32

Downside

-32.0%

Investment Thesis

A company defined by what it used to be. COVID revenue has collapsed from above USD 18 billion to roughly USD 2 billion, the core business burns USD 2-3 billion in cash a year, and investors are paying USD 47 for pipeline outcomes that are years away. The flu PDUFA on August 5 is a binary risk.

Full Report

The complete report includes a DCF valuation, comparable company analysis, and full investment thesis with risk factors.

Download Full Report (PDF)Download DCF Model

Report Details

AnalystGianfranco Cacciola

PublishedJune 8, 2026

SectorHealthcare

RatingSELL

Price Target$32

Current Price$47.08

For educational purposes only. Not investment advice. Price targets reflect analyst estimates as of the publication date.